Abstract
LDD175 (4-chloro-7-trifluoromethyl-10H-benzo[4,5]furo[3,2-b]indole-1-carboxylic acid) is a benzofuroindole compound characterized previously as a potent opener of the large conductance calcium activated (BKCa) channels. Activators of the BKCa channels are potential therapies for smooth muscle hyperactivity disorders. The present study investigates the influence of LDD175 on the mechanical activity of the ileum smooth muscle. LDD175 inhibited spontaneous contractions of the ileum in a concentration-dependent manner (pEC50=5.9 ± 0.1) (E max=96 ± 1.0% at 100 μM, n=3). It also remarkably inhibited contractions due to acetylcholine (ACh) (pEC50=5.3 ± 0.1)(E max=97.7 ± 2.3%, n=6) and electrical field stimulation (EFS) (pEC50=5.5 ± 0.1) (E max=83.3 ± 6.0%, n=6). In strips precontracted by 20 mM KCl, LDD175 significantly reduced the contractions yielding a pEC50 of 6.1 ± 0.1 and E max of 96.6 ± 0.9%, (n=6). In 60 mM KCl, a concentration-dependent inhibition was observed with respective pEC50 and E max values of 4.1 ± 0.1 and 50.8 ± 5.0% (n=3). BKCa channel blockers iberiotoxin (IbTX) and tetraethylammonium chloride (TEA, 1 mM) attenuated the relaxative effect of LDD175 but not barium chloride (BaCl2), and glibenclamide (KIR and KATP channel blockers, respectively). These data demonstrate the antispasmodic activity of LDD175 attributable to the potentiation of the BKCa channels.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Becker, M., Brenner, R., and Atkinson, N., Tissue-specific expression of a drosophila calcium-activated potassium channel. J. Neurosci., 15, 6250–6259 (1995).
Bergendal, A., Linden, A., Lotvall, J., Skoogh, B., and Lofdahl, C., Different effects of salmeterol, formoterol and salbutamol on cholinergic responses in the ferret trachea. Br. J. Pharmacol., 114(7), 1478–1482 (1995).
Borrelli, F., Capasso, F., Capasso, R., Ascione, V., Aviello, G., Longo, R., and Izzo, A., Effect of Boswellia serrata on intestinal motility in rodents: inhibition of diarrhea without constipation. Br. Jour. Pharmacol., 148, 553–560 (2006).
Brayden, J. E., Potassium channels in vascular smooth muscle, Clin. Exp. Pharmacol. Physiol., 23, 1069–1076 (1996).
Butera, J. A., Antane, S. A., Hirth, B., Lennox, J. R., Sheldon, J. H., Norton, N. W., Warga, D., and Argentieri, T. M., Synthesis and potassium channel opening activity of substituted 10H-benzo[4,5]furo[3,2-b]indole- and 5,10-dihydro-indeno[1,2-b]indole-1-carboxylic acids. Bioorg. Med. Chem. Lett., 11, 2093–2097 (2001).
Calderone, V., Large-conductance, Ca(2+)-activated K(+) channels: function, pharmacology and drugs: Curr. Med. Chem. Bentham Science Publishers, IL, USA. pp. 1385–1395 (2002).
Chang, C., Dworetzky S., Wang J., and Goldstein, M., Differential expression of the alpha and beta subunits of the large-conductance calcium-activated potassium channel: implication for channel diversity. Brain Res., Mol., 45, 33–40 (1997).
Chen, S., Inoue, R., and Ito, Y., Pharmacological characterization of muscarinic receptor-activated cation channels in guinea pig ileum. Br. J. Pharmacol, 109, 793–801 (1993).
Coghlan, M. J., Carroll, W. A., and Gopalakrishnan, M., Recent developments in the biology and medicinal chemistry of potassium channel modulators; update from a decade of progress. J. Med. Chem., 44, 1627–1653 (2001).
Cook, N. S. and Quast, U., Potassium channel pharmacology. In Cook, N.S. (Eds) Potassium channels, structure, classification, function and therapeutic potential. Ellis Horwood, Chichester, pp. 181–255 (1990).
Davies, M. P., McCurrie, J. R., and Wood, D., Comparative effects of K+ channel modulating agents on contractions of rat intestinal smooth muscle. Eur. J. Pharmacol, 297, 249–256(8) (1996).
Edwards, G. and Weston A. H., The pharmacology of ATP-sensitive potassium channels, Annu. Rev. Pharmacol. Toxicol., 33, 597–637 (1993).
Edwards, G., Niederste-Hollenberg, A., Schneider, J., Noack, T., and Weston, A., Ion channel modulation by NS1619, the putative BKCa channel opener, in vascular smooth muscle. Br. J. Pharmacol., 113, 1538–1547 (1994).
Edwards, G. and Weston, A., Pharmacology of the potassium channel openers. Cardiovasc. Drugs Ther., 9, 185–193 (1995).
Fox, A. J., Barnes, P. J., Venkatesan, P., Belvisi, M. J., Activation of large conductance potassium channels inhibits the afferent and efferent function of airway sensory nerves in the guinea pig. J. Clin. Invest. 99(3), 513–519 (1997)
Galvez, A., Gimenez-Gallego, G., Reuben, J. P., Roy-Contancin, L., Feigenbaum, P., Kaczorowski, G., and Garcia, M. L., Purification and characterization of a unique, potent, peptidyl probe for the high conductance calcium-activated potassium channel from venom of the scorpion buthus tamulus. J. Biol. Chem., 265, 11083–11090 (1990).
Garcia, M. L. and Kaczorowski, G. J., Pharmacology of high-conductance Ca2+-activated potassium channels. In: Potassium Channels Cardiovascular Biology, (Ed.) Archer, S. L. and Rusch, N.J., New York: Kluwer Academic/Plenum Publishers, pp. 219–234 (2001).
Gribkoff, V. K., Starrett, J. E. Jr., and Dworetzky, S. I., Maxi-K potassium channels: form, function, and modulation of a class of endogenous regulators of intracellular calcium. Neuroscientist, 7, 166–177 (2001).
Gormemis, A. E., Ha, T. S., Im, I., Jung, K. Y., Lee, J. Y., Park, C. S., and Kim, Y. C., Benzofuroindole analogues as potent BKCa channel openers. Chembiochem., 6, 1745–1748 (2005).
Hamilton, T. C., Weir, S. W., and Weston, T. H., Comparison of effects of BRL24915 and verapamil on electrical and mechanical activity in rat portal vein. Br. J. Pharmacol., 88, 103–111 (1986).
Kaczorowski, G. and Garcia, M., Pharmacology of voltagegated and calcium-activated potassium channels. Curr. Opin. Investig. Drugs., 9, 2269–2280 (1999).
Karaki, H., Ozaki, H., Hori, M., Mitsui-Saito, M., Amano, K., Harada, K., Miyamoto, S., Nakazawa, H., Won, K., and Sato, K., Calcium movements, distribution, and functions in smooth muscle. Pharmacol. Rev., 49, 157–230 (1997).
Kishii, K. I., Morimoto, T., Nakajima, N., Yamazaki, K., Tsujitani, M., and Takayagani, I., Effects of LP-805, a novel vasorelaxant agent, a potassium channel opener, on rat thoracic aorta. Gen. Pharmacol., 23, 347–353 (1992).
Kobayashi, H., Adachi-Akahane, S., and Nagao, T., Involvement of BKCa channels in the relaxation of detrusor muscle via β-adrenoreceptors. Eur. J. Pharmacol., 404, 231–238 (2000).
Lawson, K. E., Potassium channel activation, a potential therapeutic approach?. Pharmacol. Ther., 70(1), 39–63 (1996).
Malysz, J., Buckner, S., Daza, A., Milicic, I., Perez-Medrano, A., and Gopalakrishnan, M., Functional characterization of large conductance calcium-activated K(+) channel openers in bladder and vascular smooth muscle. Naunyn-Schmiedeberg’s Arch Pharmaco., 369, 481–489 (2004).
Marty, A., Ca2+-dependent K+ channels with large unitary conductance in chromaffin cell membranes, Nature, 291, 497–500 (1981).
Quast, U., Guillon, J., and Cavero, I., Cellular pharmacology of potassium channel openers in vascular smooth muscle., Cardiovasc. Res., 28, 805–810 (1994).
Reimann, F. and Ashcroft, F. M., Inwardly rectifying potassium channels. Curr. Opin. Cell Biol., 11, 503–508 (1999).
Sheldon, J. H., Norton, N. W., and Argentieri, T. M., Inhibition of guinea pig detrusor contraction by NS-1619 is associated with activation of BKCa and inhibition of calcium currents. J. Pharmacol. Exp. Ther., 283, 1193–1200 (1997).
Shieh C. C., Coghlan, M., Sullivan, J. P., and Gopalakrishnan, M., Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol. Rev., 52, 557–594 (2000).
Sivarao, D. V., Newberry, K., Langdon, S., Lee, A. V., Hewawasam, P., Plym, M., Signor, L., Myers, R., and Lodge, N., Effect of BMS-223131 a novel opener of large conductance Ca2+-activated K+ (maxi-K) channels on normal and stress aggravated colonic motility and visceral nociception. J. Pharmacol. Exp. Ther. Fast Forward., (2005).
Suarez-Kurtz, G., Garcia, M., and Kaczorowski, G., Effects of charybdotoxin and iberiotoxin on the spontaneous motility and tonus of different guinea pig smooth muscle tissues. J. Pharmacol. Exp. Ther., 269, 439 (1991).
Tertyshnikova, S., Knox., R., Plym, M., Thalody, G., Griffin, C., Neelands, T., Harden, D., Signor, L., Weaver, D., Myers, R., and Lodge, N., BL-1249: A putative potassium channel opener with bladder relaxant properties. J. Pharmacol. Exp. Ther., 313, 250–259 (2004).
Toro, L., Wallner., M., Meera, P., and Tanaka, Y., Maxi-KCa, a unique member of the voltage-gated K+ channel superfamily. News Physiol Sci., 13, 112–117 (1998).
Vergara, C., Latorre, R., Marrion, N., and Adelman, J., Calcium-activated potassium channels. Curr. Opin. Neurobiol., 8, 321–329 (1998).
Winquist, R., Heaney, L., Wallace, E., Baskin, R., Stein, R., and Garcia, M., Glyburide blocks the relaxation response to BRL 34915 (cromakalim), minoxidil sulfate and diazoxide in vascular smooth muscle. J. Pharmacol. Exp. Ther., 248, 149–156 (1989).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
dela Peña, I.C., Yoon, S.Y., Kim, S.M. et al. Inhibition of intestinal motility by the putative BKCa channel opener LDD175. Arch. Pharm. Res. 32, 413–420 (2009). https://doi.org/10.1007/s12272-009-1315-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-009-1315-x